Articles |
From the Institute for Medical Biology and Human Genetics (H.G.K., A.L., S.K., F.K., A.A., G.U.) and the Departments of Internal Medicine (F.H., V.M.) and Blood Transfusion (D.S.), University of Innsbruck, Innsbruck, Austria.
Correspondence to Prof Dr G. Utermann, Institute for Medical Biology and Human Genetics, Schöpfstr 41, A-6020 Innsbruck, Austria.
Abstract A high plasma concentration of lipoprotein(a) [Lp(a)] has been suggested as a risk factor for coronary heart disease (CHD), but some recent prospective studies have questioned the significance of Lp(a). Lp(a) concentrations are determined to a large extent by the hypervariable apo(a) gene locus on chromosome 6q2.7, which contains a variable number of identical tandemly arranged transcribed kringle IV type 2 repeats. The number of these repeats correlates inversely with plasma Lp(a) concentration. We analyzed whether apo(a) gene variation (kringle IV repeat number) is associated with CHD. Apo(a) genotypes were determined by pulsed-field gel electrophoresis/genomic blotting in CHD patients who had undergone angiography (n=69) and control subjects matched for age, sex, and ethnicity (n=69) and were related to Lp(a) concentration, apo(a) isoform in plasma, and disease status. Apo(a) alleles with a low kringle IV copy number (<22) and high Lp(a) concentration were significantly more frequent in the CHD group (P<.001), whereas large nonexpressed alleles were more frequent in control subjects. The odds ratio for CHD increased continuously with a decreasing number of kringle IV repeats and ranged from 0.3 in individuals with >25 kringle IV repeats on both alleles to 4.6 in those with <20 repeats on at least one allele. This provides direct genetic evidence that variation at the apo(a) gene locus, which determines Lp(a) levels, is also a determinant of CHD risk.
Key Words: kringle IV lipoprotein(a) coronary heart disease apolipoprotein(a) genetic risk factors
This article has been cited by other articles:
![]() |
F. J Khawaja and I. J Kullo Novel markers of peripheral arterial disease Vascular Medicine, November 1, 2009; 14(4): 381 - 392. [Abstract] [PDF] |
||||
![]() |
P. R. Kamstrup, A. Tybjaerg-Hansen, R. Steffensen, and B. G. Nordestgaard Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction JAMA, June 10, 2009; 301(22): 2331 - 2339. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Tsimikas, P. Clopton, E. S. Brilakis, S. M. Marcovina, A. Khera, E. R. Miller, J. A. de Lemos, and J. L. Witztum Relationship of Oxidized Phospholipids on Apolipoprotein B-100 Particles to Race/Ethnicity, Apolipoprotein(a) Isoform Size, and Cardiovascular Risk Factors: Results From the Dallas Heart Study Circulation, April 7, 2009; 119(13): 1711 - 1719. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Lanktree, C. Rajakumar, J. H. Brunt, M. L. Koschinsky, P. W. Connelly, and R. A. Hegele Determination of lipoprotein(a) kringle repeat number from genomic DNA: copy number variation genotyping using qPCR J. Lipid Res., April 1, 2009; 50(4): 768 - 772. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Luke, J. P. Kane, D. M. Liu, C. M. Rowland, D. Shiffman, J. Cassano, J. J. Catanese, C. R. Pullinger, D. U. Leong, A. R. Arellano, et al. A Polymorphism in the Protease-Like Domain of Apolipoprotein(a) Is Associated With Severe Coronary Artery Disease Arterioscler Thromb Vasc Biol, September 1, 2007; 27(9): 2030 - 2036. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Guerra, Z. Yu, S. Marcovina, R. Peshock, J. C. Cohen, and H. H. Hobbs Lipoprotein(a) and Apolipoprotein(a) Isoforms: No Association With Coronary Artery Calcification in The Dallas Heart Study Circulation, March 29, 2005; 111(12): 1471 - 1479. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Berglund and R. Ramakrishnan Lipoprotein(a): An Elusive Cardiovascular Risk Factor Arterioscler Thromb Vasc Biol, December 1, 2004; 24(12): 2219 - 2226. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. D. Wu, L. Berglund, C. Dimayuga, J. Jones, R. R. Sciacca, M. R. Di Tullio, and S. Homma High lipoprotein(a) levels and small apolipoprotein(a) sizes are associated with endothelial dysfunction in a multiethnic cohort J. Am. Coll. Cardiol., May 19, 2004; 43(10): 1828 - 1833. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Hackam and S. S. Anand Emerging Risk Factors for Atherosclerotic Vascular Disease: A Critical Review of the Evidence JAMA, August 20, 2003; 290(7): 932 - 940. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Raos and B. J. Strujic Dyslipoproteinemia and Coronary Disease Angiology, September 1, 2002; 53(5): 557 - 562. [Abstract] [PDF] |
||||
![]() |
C. Gazzaruso, A. Garzaniti, S. Giordanetti, C. Falcone, E. De Amici, D. Geroldi, and P. Fratino Assessment of Asymptomatic Coronary Artery Disease in Apparently Uncomplicated Type 2 Diabetic Patients: A role for lipoprotein(a) and apolipoprotein(a) polymorphism Diabetes Care, August 1, 2002; 25(8): 1418 - 1424. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Kang, M. Dominguez, S. Loyau, T. Miyata, V. Durlach, and E. Angles-Cano Lp(a) Particles Mold Fibrin-Binding Properties of Apo(a) in Size-Dependent Manner: A Study With Different-Length Recombinant Apo(a), Native Lp(a), and Monoclonal Antibody Arterioscler Thromb Vasc Biol, July 12, 2002; 22(7): 1232 - 1238. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Rubin, F. Paultre, C. H. Tuck, S. Holleran, R. G. Reed, T. A. Pearson, C. M. Thomas, R. Ramakrishnan, and L. Berglund Apolipoprotein [a] genotype influences isoform dominance pattern differently in African Americans and Caucasians J. Lipid Res., February 1, 2002; 43(2): 234 - 244. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Paultre, C. H. Tuck, B. Boden-Albala, D. E. Kargman, E. Todd, J. Jones, M. C. Paik, R. L. Sacco, and L. Berglund Relation of Apo(a) Size to Carotid Atherosclerosis in an Elderly Multiethnic Population Arterioscler Thromb Vasc Biol, January 1, 2002; 22(1): 141 - 146. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Paultre, T. A. Pearson, H. F. C. Weil, C. H. Tuck, M. Myerson, J. Rubin, C. K. Francis, H. F. Marx, E. F. Philbin, R. G. Reed, et al. High Levels of Lp(a) With a Small Apo(a) Isoform Are Associated With Coronary Artery Disease in African American and White Men Arterioscler Thromb Vasc Biol, December 1, 2000; 20(12): 2619 - 2624. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. KRONENBERG, E. KUEN, E. RITZ, R. JUNKER, P. KÖNIG, G. KRAATZ, K. LHOTTA, J. F. E. MANN, G. A. MÜLLER, U. NEYER, et al. Lipoprotein(a) Serum Concentrations and Apolipoprotein(a) Phenotypes in Mild and Moderate Renal Failure J. Am. Soc. Nephrol., January 1, 2000; 11(1): 105 - 115. [Abstract] [Full Text] |
||||
![]() |
F. KRONENBERG, U. NEYER, K. LHOTTA, E. TRENKWALDER, M. AUINGER, A. PRIBASNIG, T. MEISL, P. KÖNIG, and H. DIEPLINGER The Low Molecular Weight Apo(a) Phenotype Is an Independent Predictor for Coronary Artery Disease in Hemodialysis Patients: A ProspectiveFollow-Up J. Am. Soc. Nephrol., May 1, 1999; 10(5): 1027 - 1036. [Abstract] [Full Text] |
||||
![]() |
D. L. Rainwater, C. A. McMahan, G. T. Malcom, W. D. Scheer, P. S. Roheim, H. C. McGill Jr, and J. P. Strong Lipid and Apolipoprotein Predictors of Atherosclerosis in Youth : Apolipoprotein Concentrations Do Not Materially Improve Prediction of Arterial Lesions in PDAY Subjects Arterioscler Thromb Vasc Biol, March 1, 1999; 19(3): 753 - 761. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Anglés-Cano, S. Loyau, G. Cardoso-Saldaña, R. Couderc, and P. Gillery A novel kringle-4 number-based recombinant apo[a] standard for human apo[a] phenotyping J. Lipid Res., February 1, 1999; 40(2): 354 - 359. [Abstract] [Full Text] |
||||
![]() |
C. Gazzaruso, A. Garzaniti, P. Buscaglia, G. Bonetti, C. Falcone, P. Fratino, G. Finardi, and D. Geroldi Association between apolipoprotein(a) phenotypes and coronary heart disease at a young age J. Am. Coll. Cardiol., January 1, 1999; 33(1): 157 - 163. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Tate, N. Rifai, K. Berg, R. Couderc, F. Dati, G. M. Kostner, I. Sakurabayashi, and A. Steinmetz International Federation of Clinical Chemistry standardization project for the measurement of lipoprotein(a). Phase I. Evaluation of the analytical performance of lipoprotein(a) assay systems and commercial calibrators Clin. Chem., August 1, 1998; 44(8): 1629 - 1640. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Couderc, K. Peoc'h, K. Valenti, M-E. Diop, S. Bailleul, L. Kienou, F. Ferriere, and J. Etienne A Simple Electrophoretic Method for Phenotyping Apo(a): Phenotype Frequency in Healthy Subjects from Paris, France Clin. Chem., May 1, 1998; 44(5): 1047 - 1050. [Full Text] [PDF] |
||||
![]() |
P. N. Hopkins, L. L. Wu, S. C. Hunt, B. C. James, G. M. Vincent, and R. R. Williams Lipoprotein(a) Interactions With Lipid and Nonlipid Risk Factors in Early Familial Coronary Artery Disease Arterioscler Thromb Vasc Biol, November 1, 1997; 17(11): 2783 - 2792. [Abstract] [Full Text] |
||||
![]() |
M. Poon, X. Zhang, K. G. Dunsky, M. B. Taubman, and P. C. Harpel Apolipoprotein(a) Induces Monocyte Chemotactic Activity in Human Vascular Endothelial Cells Circulation, October 21, 1997; 96(8): 2514 - 2519. [Abstract] [Full Text] |
||||
![]() |
S. Kochl, F. Fresser, E. Lobentanz, G. Baier, and G. Utermann Novel Interaction of Apolipoprotein(a) With beta -2 Glycoprotein I Mediated by the Kringle IV Domain Blood, August 15, 1997; 90(4): 1482 - 1489. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. W. F. Wilson and W. B. Kannel Should We Measure Lipoprotein Lp(a)? Arch Intern Med, June 9, 1997; 157(11): 1161 - 1162. [Abstract] [PDF] |
||||
![]() |
T. Huby, C. Dachet, R. M. Lawn, J. Wickings, M. J. Chapman, and J. Thillet Functional Analysis of the Chimpanzee and Human apo(a) Promoter Sequences. IDENTIFICATION OF SEQUENCE VARIATIONS RESPONSIBLE FOR ELEVATED TRANSCRIPTIONAL ACTIVITY IN CHIMPANZEE J. Biol. Chem., June 15, 2001; 276(25): 22209 - 22214. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1996 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |